This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
Key Takeaways
- The publisher estimates that in 2019, there were 462,100 incident cases of pancreatic cancer worldwide, and expects that number to increase to 486,300 incident cases by 2028.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, poly ADP-ribose polymerase, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral or intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase II/III, Phase II, and Phase III trial results, and an expected patent expiration.
- The overall likelihood of approval of a Phase I pancreatic cancer asset is 2%, and the average probability a drug advances from Phase III is 13.8%. Drugs, on average, take 10.7 years from Phase I to approval, compared to 9.5 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 103 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for pancreatic cancer, followed by Roche
Table of Contents
OVERVIEWKEY TAKEAWAYSEPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGSKEY UPCOMING EVENTSPROBABILITY OF SUCCESSREVENUE OPPORTUNITYAPPENDIX
DISEASE BACKGROUND
TREATMENT
RECENT EVENTS AND ANALYST OPINION
KEY REGULATORY EVENTS
LICENSING AND ASSET ACQUISITION DEALS
CLINICAL TRIAL LANDSCAPE
BIBLIOGRAPHY
LIST OF FIGURES
LIST OF TABLES
